We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
Cap. Flow
-$296M
Cap. Flow %
-5.49%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$151M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$108M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$65.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$341M 6.32%
2,718,735
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$131B
$184M 3.41%
2,584,900
+66,200
+3% +$4.8M
HUM icon
3
Humana
HUM
$48.9B
$169M 3.14%
348,700
-17,000
-5% -$8.27M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$158M 2.93%
5,525,926
-502,381
-8% -$14.4M
BSX icon
5
Boston Scientific
BSX
$65.3B
$151M 2.8%
3,898,200
-471,300
-11% -$18.9M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$146M 2.7%
1,717,310
+17,600
+1% +$1.57M
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.85B
$143M 2.66%
14,567,176
+484,496
+3% +$4.9M
UNH icon
8
UnitedHealth
UNH
$344B
$135M 2.51%
267,200
-14,000
-5% -$7.36M
PFE icon
9
Pfizer
PFE
$158B
$114M 2.11%
2,599,000
-145,000
-5% -$7.05M
THRD
10
DELISTED
Third Harmonic Bio
THRD
$110M 2.04%
+5,779,071
New +$104M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$132B
$108M 2.01%
373,200
-14,000
-4% -$4.03M
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
$108M 2%
10,280,947
– –
ISRG icon
13
Intuitive Surgical
ISRG
$134B
$107M 1.99%
572,700
+55,500
+11% +$11.9M
ACET icon
14
Adicet Bio
ACET
$90.8M
$106M 1.97%
465,446
– –
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$104M 1.94%
762,600
+75,100
+11% +$12.2M
TMO icon
16
Thermo Fisher Scientific
TMO
$227B
$103M 1.9%
202,200
+88,800
+78% +$49.7M
SRPT icon
17
Sarepta Therapeutics
SRPT
$2.21B
$102M 1.88%
918,500
+898,500
+4,493% +$90.6M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$99.1M 1.84%
1,418,892
+328,492
+30% +$24.3M
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$98.8M 1.83%
17,041,668
– –
NBIX icon
20
Neurocrine Biosciences
NBIX
$16B
$95.2M 1.77%
896,545
+47,000
+6% +$4.77M
ARGX icon
21
argenx
ARGX
$61.6B
$95.2M 1.77%
269,700
+75,700
+39% +$28M
SYK icon
22
Stryker
SYK
$108B
$85.7M 1.59%
423,100
-18,000
-4% -$3.79M
ABBV icon
23
AbbVie
ABBV
$454B
$80.5M 1.49%
600,000
-199,800
-25% -$28.7M
EW icon
24
Edwards Lifesciences
EW
$49.3B
$79.8M 1.48%
966,300
-45,000
-4% -$4.33M
PMVP icon
25
PMV Pharmaceuticals
PMVP
$78M
$78.1M 1.45%
6,563,077
– –
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
  • OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.